Electronic Health Records (EHRs) hold great promise for secondary data reuse but have been reported to contain severe biases. The temporal characteristics of coding biases remain unclear. This study used a survival analysis approach to reveal temporal bias trends for coding acute diabetic conditions among 268 diabetes patients. For glucose-controlled ketoacidosis patients we found it took an av...

Bevezetés: Az elhízottak aránya évek óta Magyarországon a legmagasabb Európában. Ezen állapot közismerten növeli cukorbetegség megjelenésének valószínűségét, de kedvezőtlen hatással van vérnyomás- és vérzsírparaméterekre is. A rövid, 2-3 perces orvosi tanácsadás táplálkozási, fizikai aktivitási szokások átalakítására minimális van. Célkitűzés: Annak meghatározása, hogy három hónapos telemedicin...

Abstract Immune Checkpoint Inhibitors (ICI) have been approved since 2011 to treat patients with advanced solid and hematological malignancies had remarkable results. However, case reports of endocrine adverse events are becoming increasingly reported can be fatal if not recognized early. Here we present two unique cases rare endocrinopathies after the use ICIs. A 47 year old male metastatic me...

BACKGROUND Quality compensation programs (QCPs), also known as pay-for-performance programs, are becoming more common within managed care entities. QCPs are believed to yield better patient outcomes, yet the programs lack the evidence needed to support these claims. We evaluated a QCP offered to network primary care physicians (PCPs) within a Medicare managed care plan to determine if a positiv...

Diabetic nephropathy is a major complication of both type 1 and type 2 diabetes and the leading cause of end-stage renal disease worldwide. Strict glycemic control and renin-angiotensin system inhibition delay the progression of diabetic nephropathy but do not prevent end-stage renal disease. Thus, identification of novel pathogenic mechanisms and targetable pathways is needed to change the out...

The field of oncolytic adenovirus (OAd) therapy has undergone much growth inrecent years as improvements in vector design have resulted in augmented selectivity andmore potent anti-cancer effects. Before planning a clinical trial, the newly developedOAd must be tested in pre-clinical animal models to access efficacy and toxicity.Currently existing animal models provide very ...